Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Exclusion Criteria

• •Exclusion of tumor histology or cytology confirmed the presence of small cell lung cancer components, or squamous cell carcinoma components of more than 10%;
• •Combined with other driver mutations with known therapeutic drug, including but not limited to: ALK rearrangement, ROS1 mutation, BRAF600E mutation;
• •Previous systematic chemotherapy for advanced NSCLC;
• •Subjects with no measurable lesions;
• •Subjects with cancer meningitis and spinal cord compression;
• •Subjects with untreated central nervous system (CNS) tumor metastasis;
• •Subjects were previously treated with an anti-PD-1, anti-PD-L1 or anti-CTLA-4 agent;
• •Subjects with any active, known or suspected autoimmune disease;
• •Subjects who are now participating in other clinical studies or the last dose of prior investigational drug was given in \< 4 weeks (or 5 half-lives) from the first investigational product administration of this study;
• •Subjects who were expected to receive any other antitumor therapy (eg, other maintenance therapy for NSCLC, radiotherapy, and/or surgical excision);
• •Subjects who received major surgery within 4 weeks prior to enrollment or were not fully recovered from prior surgery;
• •Subjects with other malignancies requiring concurrent treatment;
• •Subjects with grade II or above myocardial ischemia or myocardial infarction, or subjects with arrhythmia with poor control;
• •Subjects with uncontrolled pleural/pericardial effusion, or with ascites requiring repeated drainage;
• •Subjects with uncontrolled tumor-related pain;
• •Subjects with severe allergic reactions to other monoclonal antibodies and subjects with severe allergic reactions to pemetrexed, platinum or its prophylaxis;
• •Subjects with psychological disorder, alcohol alcoholism, drug abuse or drug dependency